Abstracts tagged "Disease Activity"

Abstract Number: 0222 • ACR Convergence 2025
Evaluating the Barriers and Facilitators for Collecting and Documenting Rheumatoid Arthritis Disease Activity Measures Using a Rheumatology Provider Survey
Isaac Smith¹, Linda Tovar², Michael Battistone², Andrea Barker³, Bryant England⁴, Ankoor Shah⁵, Joshua Baker⁶, Katherine Wysham⁷, Beth Wallace⁸, Ted Mikuls⁴, Deanna Lazaro⁹, Pascale Schwab¹⁰, Paul Monach¹¹, Gail Kerr¹², Andreas Reimold¹³, Gary Kunkel², Liron Caplan¹⁴, John Richards¹⁵, Aleksander Lenert¹⁶, Andrew Jones¹⁷, Maria I. ("Maio") Danila¹⁸, Brian Sauer¹⁹, Jorge Rojas²⁰ and Grant Cannon²¹, ¹Duke University Hospital, Durham, NC, ²Salt Lake City VA, Salt Lake City, UT, ³Salt Lake City VA, Cottonwood Heights, UT, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Duke University, Durham, NC, ⁶University of Pennsylvania, Philadelphia, PA, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹VA New York Harbor Healthcare System, Brooklyn, NY, ¹⁰Oregon Health & Science University, Portland, OR, ¹¹VA Boston Healthcare System, Boston, MA, ¹²Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹³Dallas VA Medical Center, Dallas, TX, ¹⁴University of Colorado, Denver, CO, ¹⁵Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹⁶Iowa Carver College of Medicine, Iowa City, IA, ¹⁷VA Saint Louis and Washington University, Saint Louis, ¹⁸University of Alabama at Birmingham (UAB), Birmingham VA Medical Center, Birmingham, AL, ¹⁹Salt Lake City VA/University of Utah, Salt Lake City, UT, ²⁰VA Puget Sound Health Care System, Seattle, WA, ²¹University of Utah and Salt Lake City VA, Salt Lake City, UT
Background/Purpose: Collection of disease activity measures (DAMs) is a key component of high-quality care for rheumatoid arthritis (RA) patients. This study surveyed rheumatology providers at…
Abstract Number: 2456 • ACR Convergence 2025
Predictors of Real-World Remission in Patients with SLE Initiating Belimumab in the USA
Aarat M Patel¹, Renee L. Gennarelli², Temitope Bello², Ali Bonakdar² and Karen Worley³, ¹GSK, US Medical Affairs, Durham, NC, ²Cencora, Real-World Evidence, Conshohocken, PA, ³GSK, Global Real-World Evidence & Health Outcomes Research, Collegeville, PA
Background/Purpose: The Definition Of Remission in SLE (DORIS) criteria were developed to align SLE remission definitions.1,2 Post hoc analyses of clinical trial data demonstrated that…
Abstract Number: 2290 • ACR Convergence 2025
Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
Alejandro Gómez Gómez¹, Sergio H. Martínez Mateu², Jose Luis Tandaipan³, Monica Fernandez Castro⁴, Guillermo gonzalez⁵, Sheila Melchor-Díaz⁶, Miren Uriarte Ecenarro⁷, Raúl Menor Almagro⁸, Paloma Vela Casasempere⁹, Beatriz Paredes-Romero¹⁰, Judit Font-Urgelles¹¹, Paula Estrada-Alarcón¹², Sara Manrique-Arija¹³, Mª Angeles Blazquez Cañamero¹⁴, Clara Moriano¹⁵, Juan José Alegre-Sancho¹⁶, Marina Rodríguez López¹⁷, Marta López¹⁸, Gema Bonilla¹⁹, Rafaela Ortega-Castro²⁰, Sara Maria Rojas Herrera²¹, Ignacio Braña²², Lilian López-Núñez²³, Javier Narváez²⁴, Jose Rosas Gómez de Salazar²⁵, Ruben D. López-Sánchez²⁶, Carles Galisteo Veiga²⁷, Javier Martínez-Ferrin²⁸, Jose Javier Pérez Venegas²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Lara Sánchez Bilbao³², José Andrés Román Ivorra³³, Rafael Cáliz-Cáliz³⁴, Belén Serrano-Benavente³⁵, Sabela Fernández-Aguado³⁶, Natalia Boix- Martí³⁷, Eric Kirkegaard-Biosca³⁸, Iago Alvarez Saez³⁹, Ares Selles-Rius⁴⁰, Maribel Pérez⁴¹, Juan Cañete⁴², Sara Marsal¹ and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁵Hospital Universitario de A Coruña, A Coruña, Spain, ⁶Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹³Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁴Hospital Ramon y Cajal, Madrid, Spain, ¹⁵Hospital León, LEON, Castilla y Leon, Spain, ¹⁶Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁷Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹⁸Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ²⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²¹Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ²²Hospital Universitario Central de Asturias, Oviedo, Spain, ²³Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁶Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁷Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²⁸Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ²⁹Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ³⁴Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁵Hospital Gregorio Marañon, Madrid, Spain, ³⁶Hospital Universitario de Pontevedra, Pontevedra, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Hospital Univetsitari Vall d'Hebron, Ophthalmology Department, Barcelona, Spain, ³⁹Hospital Univetsitari Vall d'Hebron, Maxilofacial Surgery Department, Barcelona, Spain, ⁴⁰Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Barcelona, Spain, ⁴²Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Assessing clinical improvements in Sjögren's Disease (SjD) is challenging. Our objective was to describe patterns of improvement in SjD using ESSDAI and ESSPRI indices…
Abstract Number: 1831 • ACR Convergence 2025
Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Christian Wright¹, Miles Smith², Rufei Lu², Catriona Wagner³, Aleksandra Bylinska², Carla Guthridge², Nicholas Domingez², Susan Macwana², Wade DeJager⁴, Marci Beel⁵, Joan Merrill⁶, Eliza Chakravarty², Ellen Goldmuntz⁷, Study Team ALE⁰⁶ Clinical⁸, Judith James² and Joel Guthridge², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁷NIAID/ NIH, Washington, DC, ⁸Autoimmunity Center of Excellence, Oklahoma City, OK
Background/Purpose: : Systemic Lupus Erythematosus (SLE) follows a characteristic relapsing-remitting course with unpredictable flares interspersed with periods of relative quiescence. Mycophenolate mofetil (MMF) has emerged…
Abstract Number: 1491 • ACR Convergence 2025
Feasibility of Extrarenal Systemic Lupus Erythematosus Disease Modification in GLADEL 2.0, a Latin American Cohort
julián Barahona-correa¹, Santiago Bernal-Macías², Daniel Fernandez³, Óscar Muñoz², Lucia Hernández⁴, Erika Susana Palacios Santillan⁵, Laura Maurelli⁶, Paula Alba⁷, Veronica Saurit⁸, Lucila Garcia⁹, María Emilia Sattler¹⁰, Maria Constanza Bertolaccini¹¹, Marina Laura Micelli¹², Graciela Gomez¹³, Micaela A. Cosatti¹⁴, Ana Carolina Ralle¹⁵, Joaquín Martinez Serventi¹⁶, Ana Silva¹⁷, ODIRLEI MONTICIELO¹⁸, Ángela Luzia Branco Pinto Duarte¹⁹, Laíssa Cristina Alves Alvino²⁰, Eduardo Borba²¹, Eloisa Bonfa²¹, Edgard dos Reis-Neto²², Iris Guerra Herrera²³, Milena Mimica²⁴, Gustavo Aroca Martínez²⁵, Lorena Gómez Escorcia²⁶, Carlos Alberto Cañas²⁷, Gerardo Quintana-Lopez²⁸, Carlos Toro-Gutierrez²⁹, José Maximiliano Martínez Pérez³⁰, Reyna Elizabeth Sánchez-Briones³¹, Mario Pérez Cristóbal³², Eduardo Martin-Nares³³, Yaneli Juarez-Vicuña³⁴, Ignacio García-Valladares³⁵, Rodrigo Ortiz Hernández³⁶, Jorge Antonio Esquivel Valerio³⁷, Maria Isabel Acosta³⁸, Astrid Paats³⁹, Jorge Cieza Calderón⁴⁰, Manuel Ugarte-Gil⁴¹, Armando Calvo⁴², Rodamin Ambiorix Alvarez Santana⁴³, Analía Cánepa⁴⁴, Carina Pizzarossa⁴⁴, Federico Zazzetti⁴⁵, Ashley Orillion⁴⁶ and Cristina Drenkard⁴⁷, ¹Colombian Association of Rheumatology (ASOREUMA), Bogotá, Colombia; Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, ²Hospital Universitario San Ignacio, Bogotá, Colombia, Bogotá, Colombia, ³Facultad de Medicina, Pontificia Universidad Javeriana, Bogotá, Colombia; Departamento de Medicina Interna, Unidad de Reumatología, Hospital Universitario San Ignacio, Bogotá, Colombia, BOGOTA, Colombia, ⁴Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, Rosario, Argentina, ⁵Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁶Hospital Italiano de Córdoba, Córdoba, Argentina, Córdoba, Argentina, ⁷Hospital Córdoba y Sanatorio Allende, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina, Cordoba, Argentina, ⁸Hospital Privado Universitario de Cordoba, Córdoba, Argentina, Córdoba, Argentina, ⁹Hospital San Martin de La Plata, La Plata, Argentina, La Plata, Argentina, ¹⁰Sanatorio Británico, Rosario, Argentina, Rosario, Argentina, ¹¹Hospital Ángel C. Padilla, Tucumán, Argentina, Tucumán, Argentina, ¹²Hospital J.M Ramos Mejía, Buenos Aires, Argentina, Buenos Aires, ¹³Instituto de Investigaciones Médicas Alfredo Lanari, Universidad de Buenos Aires, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁴CEMIC Centro de Educación Médica e Investigaciones Clínicas ‘‘Norberto Quirno,’’ Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁵Hospital Señor del Milagro Salta, Salta, Argentina, Salta, Argentina, ¹⁶Hospital General de Agudos Dr. Juan A. Fernández, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹⁷Hospital das Clinicas da Universidade Federal de Goias, Goiania, Brazil, Goiania, Brazil, ¹⁸Hospital de Clínicas de Porto Alegre, Universidade Federal Do Rio Grande Do Sul, Porto Alegre, Brazil, PORTO ALEGRE, Rio Grande do Sul, Brazil, ¹⁹Universidad Federal de Pernambuco, Recife, Brazil, Recife, Brazil, ²⁰Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, ²¹Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ²²Escola Paulista de Medicina / Universidade federal de São Paulo (EPM / Unifesp), São Paulo, Brazil, São Paulo, Brazil, ²³Hospital del Salvador Santiago de Chile, Santiago, Chile, Santiago, Chile, ²⁴Facultad de Medicina y Ciencia, Universidad San Sebastián, Santiago, Chile, Santiago, Chile, ²⁵Universidad Simón Bolívar, Barranquilla, Colombia y Clínica de la Costa, Barranquilla, Colombia, ²⁶Clínica de la Costa y Universidad Simón Bolívar Barranquilla, Barranquilla, Colombia, Barranquilla, Colombia, ²⁷Fundación Valle del Lili, Universidad Icesi, Cali, Colombia, Cali, Colombia, ²⁸Facultad de Medicina, Universidad Nacional de Colombia; Hospital Universitario Fundación Santa Fe de Bogotá; Hospital Universitario Nacional de Colombia, Bogotá, Colombia, Bogotá, Colombia, ²⁹Pontificia Universidad Javeriana de Cali, Cali, Colombia, Cali, Colombia, ³⁰Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador, Guayaquil, Ecuador, ³¹Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City, Mexico, Mexico City, Mexico, ³²Hospital de Especialidades del Centro Médico Nacional SXXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico, Mexico City, Mexico, ³³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, Mexico City, Mexico, ³⁴Instituto Nacional de Cardiología Ignacio Chávez, Mexico City, Mexico, Mexico City, Mexico, ³⁵Centro de Estudios de Investigación Básica y Clínica, S.C., Guadalajara, Mexico, Guadalajara, Mexico, ³⁶Facultad de Medicina de la Universidad Autónoma de San Luis Potosí y Hospital Central "Dr. Ignacio Morones Prieto," San Luis Potosi, Mexico, San Luis Potosi, Mexico, ³⁷Universidad Autónoma de Nuevo León, Rheumatology Service, Hospital Universitario "Dr. José Eleuterio González", Monterrey, Nuevo León, México., MONTERREY, Mexico, ³⁸Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asuncion, Paraguay, ³⁹Facultad de Ciencias Medicas, Universidad Nacional de Asunción, San Lorenzo, Paraguay, Asunción, Paraguay, ⁴⁰Hospital Nacional Edgardo Rebagliati Martins-EsSalud, Lima, Peru, Lima, Peru, ⁴¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ⁴²Hospital Nacional Cayetano Heredia Universidad Peruana Cayetano Heredia, Lima, Peru, Jesús María, Peru, ⁴³Hospital Docente Padre Billini, Santo Domingo, Distrito Nacional, Dominican Republic, ⁴⁴Hospital de Clínicas, Facultad de Medicina, UDELAR, Montevideo, Uruguay, Montevideo, Uruguay, ⁴⁵Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴⁶Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ⁴⁷Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA
Background/Purpose: The concept of disease modification (DM) has been recently introduced to improve the long-term care of patients (pts) with SLE. DM is defined as…
Abstract Number: 1320 • ACR Convergence 2025
Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
Noah Frechette¹, Elena myasoedova¹, Iqra Javed¹, Roslin George¹, Sara Achenbach² and Cynthia Crowson³, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, ³Mayo Clinic, Stewartvillle, MN
Background/Purpose: Venous thromboembolism (VTE) is more common in patients with rheumatoid arthritis (RA) and can present as deep vein thrombosis (DVT) or pulmonary embolism (PE).…
Abstract Number: 0917 • ACR Convergence 2025
Synovial Tissue Neutrophils are Associated with Disease Activity and Early Remission in Rheumatoid Arthritis
Annabelle Small¹, Vincent Wong², Christopher Altmann¹, Helen Weedon³, Malcolm Smith⁴, Susanna Proudman⁵ and Mihir Wechalekar⁶, ¹Flinders University, Bedford Park, South Australia, Australia, ²College of Medicine and Public Health, Bedford Park, South Australia, Australia, ³Flinders University of South Australia, Bedford Park, South Australia, Australia, ⁴Flinders University, Adelaide, South Australia, Australia, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Flinders Medical Centre and Flinders University, Bedford Park, South Australia, Australia
Background/Purpose: Neutrophils drive local pathology of rheumatoid arthritis (RA) in the synovial tissue (ST) through local production inflammatory mediators, cytokines, and extracellular traps. However, despite…
Abstract Number: 0725 • ACR Convergence 2025
Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis
Rennie Rhee¹, Christine Yeung², Darrin White³, Mary Gibson³, Jessica Nguyen⁴, Cristina Burroughs⁵, Jennifer Gordon⁶, Noam A. Cohen⁴, Jeffrey Morris⁴ and Peter Merkel¹, ¹University of Pennsylvania, Philadelphia, PA, ²Vasculitis Patient-Powered Research Network, Philadelphia, PA, ³². Patient Research Partner, Vasculitis Patient-Powered Research Network, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵University of South Florida, Tampa, FL, ⁶Vasculitis Foundation, Kansas City, MO
Background/Purpose: Sinus and nasal symptoms are common and associated with a higher risk of relapse in patients with ANCA-associated vasculitis (AAV). Previously, our group found…
Abstract Number: 0440 • ACR Convergence 2025
The Painful Truth: Non-Articular Pain’s Impact on Rheumatoid Arthritis Assessment after Initiating a new DMARD for Active Disease
Charis Meng¹, Jing Song², Lutfiyya muhammad³, Caci Julia⁴, Tuhina Neogi⁵, Marcy Bolster⁶, Wendy Marder⁷, Clifton Bingham⁸ and Yvonne Lee⁹, ¹Hospital for Special Surgery, New York, NY, ²Northwestern University Feinberg School of Medicine, Worthington, MN, ³Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Hospital for Special Surgery, New York, ⁵Boston University School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Concord, MA, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins University, Baltimore, MD, ⁹Northwestern University, Chicago, IL
Background/Purpose: RA-related pain is typically thought of as pain in the joints. However, non-articular pain (NAP) is also common, persisting in 1/3 of patients with…
Abstract Number: 0199 • ACR Convergence 2025
Pain Phenotypes and Social Determinants of Health in Chronic Chikungunya Arthritis: A Cross-Sectional Study
Abebawork Adem¹, Alfonso Sucerquia², Jose Forero³, Juan Alzate², Larry Moreland⁴, Gary Firestein⁵, Andres Cadena⁶ and Aileen Chang⁷, ¹George Washington University, Washington, DC, DC, ²The George Washington University, Arlington, ³The George Washington University, Arlington, VA, ⁴University of Colorado, Denver, CO, ⁵University of California, San Diego, San Diego, CA, ⁶Clinica de la Costa, Barranquilla, Colombia, ⁷The George Washington University, Washington
Background/Purpose: Chronic chikungunya arthritis (CCA) is a long-term sequela of chikungunya virus infection marked by persistent pain, disability, and reduced quality of life. While nociplastic,…
Abstract Number: 2430 • ACR Convergence 2025
Disease Activity Independently Correlates with Cognitive Impairment in Systemic Lupus Erythematosus
Steven Beiser¹, Asma Qureshi¹, Komel Safdar², Zachary Orban¹, Mary Carns², Vanessa Manada De Lobos¹, Cecilia Stumpf³, Mohammad Daud Khan¹, Tyler Therron⁴, Anh Chung¹, Katherine Puev¹, Neil Pillai¹, Kathleen Aren⁵, John F Seagrist², Jing Song⁶, Jason Ross¹, Harris R Perlman², Yvonne Lee², Deborah Rachelle Winter⁷, Borna Bonakdarpour¹, Mariam Siddiqui⁸, Laura Arneson², Rosalind Ramsey-Goldman⁹, Lutfiyya muhammad⁹, Mary Mahieu⁹, Irene Blanco¹⁰, Eric Larson¹, Elena Grebenciucova¹ and Carla Marie Cuda², ¹Northwestern University, Chicago, ²Northwestern University, Chicago, IL, ³Northwestern University, Elmhurst, IL, ⁴Northwestern Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University Division of Rheumatology, Chicago, IL, ⁶Northwestern University Feinberg School of Medicine, Worthington, MN, ⁷Northwestern University, Skokie, IL, ⁸Northwestern, Chicago, IL, ⁹Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Northwestern University, Oak Park, IL
Background/Purpose: Mechanisms driving cognitive impairment (CI) in systemic lupus erythematosus (SLE) remain poorly understood; conflicting results exist regarding the relationship between CI and disease activity.…
Abstract Number: 2278 • ACR Convergence 2025
Neuroimmune modulation for the Treatment of Rheumatoid Arthritis: Results at 12 months from a Randomized, Sham-Controlled, Double-Blind Study
John Tesser¹, Angela Crowley², Jane Box³, Joshua June⁴, Pendleton Wickersham⁵, Guillermo Valenzuela⁶, Norman Gaylis⁷, Gordon Lam⁸, Leroy Pacheco⁹, David Ridley¹⁰, Gineth Pinto-Patarroyo¹¹, Stuart Novack¹², Melvin Churchill¹³, Minna Kohler¹⁴, Eric Lee¹⁵, Jose A Pando¹⁶, Glenn R. Parris¹⁷, Jeff Peterson¹⁸, Tina Shah¹⁹, Atul Singhal²⁰, Victoria Vuong²¹, Jeffrey Curtis²² and David Chernoff²³, ¹Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ²Illinois Bone and Joint Institute - Hinsdale Orthopaedics, Hinsdale, IL, ³DJL Clinical Research, PLLC, Charlotte, NC, ⁴Great Lakes Center of Rheumatology, Lansing, MI, ⁵Arthritis Associates PA, San Antonio, TX, ⁶Integral Rheumatology & Immunology Specialists, Plantation, FL, ⁷Arthritis & Rheumatic Disease Specialties, Aventura, FL, ⁸Arthritis and Osteoporosis Consultants of the Carolinas, Cornelius, NC, ⁹Albuquerque Ctr for Rheumatology, Albuquerque, NM, ¹⁰Saint Paul Rheumatology, Eagan, MN, ¹¹Annapolis Rheumatology, Herndon, VA, ¹²Nuvance Health network, NORWALK, CT, ¹³Arthritis Center of Nebraska, Lincoln, NE, ¹⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁵Inland Rheumatology and Osteoporosis Medical Group, Upland, CA, ¹⁶Delaware Arthritis, Lewes, DE, ¹⁷PARRIS & ASSOCIATES, Lilburn, GA, ¹⁸Western Washington Arthritis Clinic, Seattle, WA, ¹⁹Kansas City Physician Partners, Kansas City, MO, ²⁰SouthWest Arthritis Research Group, Mesquite, TX, ²¹Long Island Regional Arthritis & Osteoporosis Care, Hicksville, NY, ²²University of Alabama at Birmingham, Birmingham, AL, ²³SetPoint Medical, Sausalito, CA
Background/Purpose: Neuroimmune modulation by electrical stimulation of the left cervical vagus nerve represents a novel treatment option for rheumatoid arthritis (RA). We present 12-month efficacy…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1472 • ACR Convergence 2025
Characteristics and Predictors of LLDAS in Survivors of Early Active Lupus: Insights from a Decade-Long Cohort
Amirtha Gopalan¹, keerthi vardhan yerram², Mahesh Gaikwad² and Liza rajasekhar³, ¹Nizams Institute of Medical Sciences, Hyderabad, Hyderabad, Telangana, India, ²Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, ³Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India
Background/Purpose: LLDAS is a desirable state in lupus, with ongoing global reports on its durability and outcomes. The relationship between LLDAS, baseline characteristics, and drug…
Abstract Number: 1318 • ACR Convergence 2025
Diagnostic Delay in Rheumatoid Arthritis and its Impact on Radiographic Outcomes: A Systematic Review and Meta-analysis of 100,066 Patients
Mohamed Abdelsalam¹, Menat Alla Ayman Ali Mahdy², Bassant Elaraby Elsayed Badwy², Maryam Lasheen³, Omar Sameh Nabil El Sedafy¹, Hadeer Hafez⁴ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt
Background/Purpose: Timely diagnosis is the cornerstone of effective rheumatoid arthritis (RA) management, with early treatment shown to significantly improve outcomes through a treat-to-target strategy. While…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].